Last updated on June 2019

Study of Zanubrutinib (BGB-3111) in Patients With Marginal Zone Lymphoma

Brief description of study

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).

Detailed Study Description

This is a Phase 2, open-label study of zanubrutinib in approximately 65 patients with R/R MZL. The study will evaluate efficacy, as measured by overall response rate, safety and tolerability.

Clinical Study Identifier: NCT03846427

Find a site near you

Start Over

Peter MacCallum Cancer Centre

Melbourne, Australia
  Connect »

Box Hill Hospital (AUS)

Box Hill, Australia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.